Private placement in EXACT Therapeutics AS (NO) – NOK 25 million

Carnegie acted as sole bookrunner in EXACT Therapeutics NOK 25 million private placement at a subscription price of NOK 12 per share.

EXACT-Tx is a Norwegian clinical-stage precision medicine company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy) and brain diseases.